LianBio
LIANY · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.12 | -0.00 | 0.04 | -0.09 |
| FCF Yield | 13.06% | 53.60% | -57.01% | -24.99% |
| EV / EBITDA | -7.07 | 0.15 | -0.93 | -2.24 |
| Quality | ||||
| ROIC | -62.37% | -17.02% | -41.60% | -47.42% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.51 | 0.83 | 0.90 | 0.84 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -98.55% | 356.23% | 38.89% | -66.45% |
| Safety | ||||
| Net Debt / EBITDA | -15.88 | -1.39 | 0.68 | 1.14 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -70.59 | -1,104.90 | -527.71 | -2,243.34 |